Business Context and Reporting Period
This Form 8-K is a current report filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on September 19, 2024. The filing discloses a material change in executive leadership, specifically the appointment of a new Chief Financial Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Appointment: The Board appointed Ozan Pamir as Chief Financial Officer (CFO) and Principal Accounting Officer, effective October 21, 2024.
- Leadership Transition: Mr. Pamir replaces James Lee, who served as Interim CFO. Mr. Lee will transition to the role of Controller.
- Compensation Package:
- Annual base salary: $400,000.
- Discretionary target annual bonus: 50% of base salary (pro-rated for 2024).
- Equity grant: Stock option with an initial grant date value of $360,000.
- Vesting schedule: One-third vests on the one-year anniversary; the remainder vests in 24 monthly installments.
- Severance Terms: In the event of termination without "cause," Mr. Pamir is entitled to nine months of base salary continuation.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No specific risks or contingencies related to financial performance are disclosed in this document.
Investor Verification Checklist
- Verify the effective date of the CFO transition (October 21, 2024) and the interim status of the previous CFO.
- Review the attached Offer Letter (Exhibit 10.1) for full details on performance goals and vesting conditions.
- Confirm the impact of the new CFO's background (previously CFO of 180 Life Sciences Corp.) on future financial strategy.
- Note that the filing references a press release issued on September 20, 2024 (Exhibit 99.1) for public announcement details.